长春中医药大学学报Issue(1)：141-143,3.DOI:10.13463/j.cnki.cczyy.2016.01.048
散结镇痛胶囊联合米非司酮治疗子宫内膜异位症
Sanjie Zhentong capsule in combined with mifepristone in treatment of endometriosis
摘要
Abstract
Objective To explore the clinical efficacy of Sanjie Zhentong capsule in combined with mifepristone in the treatment of endometriosis(EMT). Methods A total of 60 patients with EMT were included in the study and randomized into the observation group and the control group. The patients in the control group were orally given mife-pristone the fifth day of menstrual cycle,12. 5 mg / time,1 time / d. On this basis,the patients in the observation group were given Sanjie Zhentong capsule,1. 6 g / once,3 times/ d. The patients in the two groups were given a continuous 3-month treatment. The levels of peripheral blood PGF2α,CA125 ,and serum FSH,LH,before and after treatment in the two groups were detected. The clinical effect and adverse reactions in the two groups were observed. Results The de-creased degree of CA125 and PGF2α levels after treatment in the observation group was significantly superior to that in the control group(P ﹤ 0. 05). The decreased degree of FSH,LH,E2 and P levels after treatment in the observation group was significantly superior to that in the control group(P ﹤ 0. 05). The total effective rate(95. 0℅ )and the oc-currence rate of adverse reactions(8. 3℅ )in the observation group were significantly superior to those in the control group(80. 0℅ and 26. 7℅ ,respectively)( P ﹤ 0. 05). Conclusions Sanjie Zhentong capsule in combined with mifepristone in the treatment of EMT can significantly reduce the levels of CA125 and PGF2α,regulate the levels of FSH,LH,E2 and P,and inhibit the hyperplasia of ectopic endometrium with a satisfactory clinical effect and less ad-verse reactions;therefore,it deserves to be widely recommended in the clinic.关键词
米非司酮/散结镇痛胶囊/子宫内膜异位症Key words
mifepristone/Sanjie Zhentong capsule/endometriosis分类
医药卫生引用本文复制引用
陈晓莉..散结镇痛胶囊联合米非司酮治疗子宫内膜异位症[J].长春中医药大学学报,2016,(1):141-143,3.基金项目
河北省张家口市科技攻关项目（0921122D）。 （）
